Clinical trial
Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy…
NCT00098306 · ViiV Healthcare, Industry · Completed
Key facts
| NCT number | NCT00098306 |
|---|---|
| Title | Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects |
| Official title | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced HIV-1 Infected Subjects. |
| Acronym | MOTIVATE 1 |
| Lead sponsor | ViiV Healthcare, Industry |
| Collaborators | Pfizer Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Maraviroc (UK-427, 857), Optimized Background Therapy, Placebo |
| Enrollment | 601 |
| Start date | Nov 1, 2004 |
| Primary completion | Apr 1, 2007 |
| Completion | Apr 1, 2011 |
| First posted | Dec 7, 2004 |
| Last update posted | Apr 27, 2012 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: